The role of PARP inhibitors in BRCA mutated pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) accounts for about 3% of all cancers in the United States and about 7% of all cancer deaths. Despite the lower prevalence relative to other solid tumors, it is one of the leading causes of cancer-related death in the US. PDAC is highly resistant to chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Jeffrey, Chung, Su Yun, Parakrama, Ruwan, Fayyaz, Fatima, Jose, Jyothi, Saif, Muhammad Wasif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120537/
https://www.ncbi.nlm.nih.gov/pubmed/34025781
http://dx.doi.org/10.1177/17562848211014818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120537/
https://www.ncbi.nlm.nih.gov/pubmed/34025781
http://dx.doi.org/10.1177/17562848211014818

Ejemplares similares